The DOI matches its Crossref record.
Lutetium-labelled peptides for therapy of neuroendocrine tumours
Open accessAbstract
Treatment with radiolabelled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumours. Symptomatic improvement may occur with (177)Lu-labelled somatostatin analogues that have been used for peptide receptor radionuclide therapy (PRRT). The results obtained with (177)Lu-[DOTA(0),Tyr(3)]octreotate (DOTATATE) are very encouraging in terms of tumour regression. Dosimetry studies with (177)Lu-DOTATATE as well as the limited side effects with additional cycles of (177)Lu-DOTATATE suggest that more cycles of (177)Lu-DOTATATE can be safely given. Also, if kidney-protective agents are used, the side effects of this therapy are few and mild and less than those from the use of (90)Y-[DOTA(0),Tyr(3)]octreotide (DOTATOC). Besides objective tumour responses, the median progression-free survival is more than 40 months. The patients' self-assessed quality of life increases significantly after treatment with (177)Lu-DOTATATE. Lastly, compared to historical controls, there is a benefit in overall survival of several years from the time of diagnosis in patients treated with (177)Lu-DOTATATE. These findings compare favourably with the limited number of alternative therapeutic approaches. If more widespread use of PRRT can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable neuroendocrine tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Imaging biomarker roadmap for cancer studies
O'Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., Boellaard, R., Bohndiek, S. E., Brady, M., Brown, G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.162 · Cited by 1,091
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
Dash, A., Pillai, M. R. A., & Knapp, F. F. (2015) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-014-0315-z · Cited by 386
Ljungberg, M., Celler, A., Konijnenberg, M. W., Eckerman, K. F., Dewaraja, Y. K., & Sjögreen-Gleisner, K. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.159012 · Cited by 369
Delker, A., Fendler, W. P., Kratochwil, C., Brunegraf, A., Gosewisch, A., Gildehaus, F. J., Tritschler, S., Stief, C. G., Kopka, K., Haberkorn, U., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3174-7 · Cited by 322
Banerjee, S., Pillai, M. R. A., & Knapp, F. F. (. (2015) · Chemical Reviews · doi:10.1021/cr500171e · Cited by 321
Metadata
- Authors
- Kam, B. L. R., Teunissen, J. J. M., Krenning, E. P., de Herder, W. W., Khan, S., van Vliet, E. I., & Kwekkeboom, D. J.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2012-02
- Volume
- 39
- Issue
- S1
- Pages
- 103-112
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2079241416
- Cited by
- 246
- References
- 0
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lutetium-labelled peptides for therapy of neuroendocrine tumours. https://app.cochat.ai/papers/10.1007/s00259-011-2039-y
- The paper
- Kam, B. L. R., Teunissen, J. J. M., Krenning, E. P., de Herder, W. W., Khan, S., van Vliet, E. I., & Kwekkeboom, D. J. (2012). Lutetium-labelled peptides for therapy of neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-011-2039-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.